Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review.

ABSTRACT: In clinical trials, the percentage of patients discontinuing treatment with ocrelizumab due to adverse events was low. However, real-world populations are often more diverse than randomized controlled trials (RCTs), therefore it is important to assess discontinuation rates in real-world studies. This systematic literature review (SLR) was conducted to identify real-world discontinuation and persistence data for ocrelizumab in studies of patients with relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Searches were conducted in MEDLINE and Embase to identify relevant real-world studies that met pre-determined Population, Intervention, Comparison, Outcomes, and Study (PICOS) criteria. Only articles published in English were included, but the stud

SUBMITTER: Petrie JL 

PROVIDER: S-EPMC11541982 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature